In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Validating Europe's De-Risked Approach

Executive Summary

Novartis' deal on COPD compound AD 237, co-developed by Vectura and Arakis, proves that low-risk "re-profilers" can win big bucks. But the program must be right, and so must the partner's portfolio. It isn't about the technology-it's about the product.

You may also be interested in...



Macromolecules & Spec Pharma: The Good News in Drug Delivery

Two major changes have transformed the prospects for drug-delivery companies: the rise of spec pharma and Big Pharma's embrace of large-molecule therapeutics. A new group of start-ups represents strategies to take advantage of both opportunities.

Drug Delivery Heats Up

The prices of drug-delivery deals have been going up -- thanks to spec pharma which has now turned almost entirely to the products of drug delivery and reformulation to re-stock their pipelines. Meanwhile, Big Pharma remains a minor player in small-molecule reformulation, but is increasingly active when it comes to macromolecules.

Innovation: Defined by the Customer, Not by Pharma

All drug company executives agree that innovation is the answer to the industry's woes-R&D productivity, pricing, perception, the lot. But they differ on what innovation means.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1123738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel